Q-omics provides the consensus-scored PNMA8B profile across patient tissues and cancer cell-line models. PNMA8B expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, PNMA8B is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, PNMA8B RNA expression shows 23,214 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight HNSC, KICH, and GBM as cancer lineages where PNMA8B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PNMA8B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PNMA8B survival associations across molecular data types. PNMA8B RNA expression shows survival associations in the most cancer types (27), followed by mutation status (11) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PNMA8B RNA expression–survival associations across cancer types. High PNMA8B expression shows unfavorable associations in ACC, but favorable associations in HNSC, KIRP, LGG, CESC and KIRC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for PNMA8B RNA expression.
This table summarizes PNMA8B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in KICH for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for PNMA8B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PNMA8B shows lower tumor expression in KICH, BLCA, UCEC, BRCA, COAD and PRAD. The KICH box plot shows higher PNMA8B RNA expression in normal versus tumor tissue (log2 FC = −0.898, t-test p < 0.001).
This table shows molecular features associated with PNMA8B in patient tissues and cancer cell lines. In patient samples, PNMA8B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PNMA8B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and LARGE_INTESTINE.
